Vivos Therapeutics signals transformative growth with SCN acquisition and expects positive cash flow by end of 2025

Stock Information for Vivos Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vivos Therapeutics Inc.

Vivos Therapeutics Receives Medicare Approval for VidaSleep(TM) Oral Appliance
New Clinical Trial Data Published Showing Positive Results from Use of Vivos Technology to Treat Obstructive Sleep Apnea in Children
Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update
Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call
Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada
Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update
Vivos Therapeutics Schedules Release of Full Year 2024 Financial Results and Conference Call

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.